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Cardiofaciocutaneous (CFC) syndrome is a multiple congenital anomalies/mental retardation syndrome
characterized by congenital heart defects, characteristic facial appearance, short stature, ectodermal
abnormalities and mental retardation. It was described in 1986, and to date is of unknown genetic
etiology. All reported cases are sporadic, born to non-consanguineous parents and have apparently
normal chromosomes. Noonan and Costello syndromes remain its main differential diagnosis. The recent
finding of PTPN11 missense mutations in 45 – 50% of the Noonan patients studied with penetrance of
almost 100% and the fact that in animals mutations of this gene cause defects of semilunar
valvulogenesis, made PTPN11 mutation screening in CFC patients a matter of interest. We sequenced the
entire coding region of the PTPN11 gene in ten well-characterised CFC patients and found no base
changes. We also studied PTPN11 cDNA in our patients and demonstrated that there are no interstitial
deletions either. The genetic cause of CFC syndrome remains unknown, and PTPN11 can be reasonably
excluded as a candidate gene for the CFC syndrome, which we regard as molecular evidence that CFC
and Noonan syndromes are distinct genetic entities.
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Introduction
Cardiofaciocutaneous (CFC) syndrome (MIM 115150) is a
multiple congenital anomalies/mental retardation
syndrome characterised by congenital heart defects, charac-
teristic facial appearance, short stature, ectodermal
abnormalities, and mental retardation.1 A recent review
has identified 54 published classical cases of CFC syndrome.
All cases were sporadic, with apparently normal chromo-
somes, born to non-consanguineous parents and
presenting the same unique combination of findings and
natural history.2
The CFC phenotype comprises a characteristic facial
appearance, congenital heart defects (pulmonic stenosis,
37%; atrial septal defect, 35%; hypertrophic cardiomyopa-
thy, 11%), mental retardation/developmental delay (81%),
speech delay (46%), short stature (78%) and hypotonia
(28%). The typical craniofacial manifestations include rela-
tive macrocephaly, high forehead, bitemporal constriction,
supraorbital hypoplasia, short nose with depressed nasal
bridge and anteverted nostrils, apparently low-set and
posteriorly angulated ears, hypertelorism, ptosis, epicanthal
folds, and downslanting of palpebral fissures. All patients
had an ectodermal abnormality consisting of sparse, slowly
growing and curly hair, sparse or absent eyelashes and
eyebrows, follicular keratosis or ulerythema ophryogenes,
ichthyosis, hyperkeratosis, generalized hyperpigmentation,
haemangiomas, hyperelastic skin, cutis marmorata, cafe´-
au-lait patches, and/or slowly growing nails.
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In spite of the controversy about the distinction between
CFC and Noonan syndrome (NS) most of the time a refined
clinical evaluation is sufficient for the differential diagnosis.
Although phenotypic similarity between CFC and NS exists,
especially regarding cardiac defects, craniofacial findings,
short stature and congenital lymphedema, there are clear
differences in clinical manifestations and natural history
that separate the two conditions.3 – 5
Autosomal dominant inheritance is evident in many NS
families, and genetic heterogeneity has also been demon-
strated.6 Linkage studies have defined a region of
approximately 7.5 Mb on the long arm of chromosome 12
(12q24) as a candidate region for a gene(s) causing NS6 – 9
(Figure 1). The recent demonstration of mutations in
PTPN11, the gene encoding the non-receptor-type protein
tyrosine phosphatase SHP-2 (src homology region 2-domain
phosphatase-2)10 (Figure 2), in 45 – 50% of the studied
patients of NS,9,11 has enabled an initial genotype – pheno-
type analysis. This has also shown that pulmonic stenosis is
more prevalent in the group of NS patients who had a
PTPN11 mutation than in the group without a mutation
(70.6 vs 46.2%; P50.01). The identification of a PTPN11
mutation in a family segregating the Noonan-like/multiple
giant-cell lesion syndrome,11 and in LEOPARD syndrome,12
suggests a considerable phenotypic range due to mutations
in this gene making it necessary to study the possible role
of this gene in CFC syndrome.
Patients
We studied ten CFC patients (nine males and one female)
(Figure 3), randomly selected from a larger group of CFC
patients followed by a group of clinical geneticists in Brazil,
Italy and North America, experienced with CFC syndrome
and its nosology with the Noonan and Costello syndromes.
In all cases the clinical diagnosis was considered incontro-
vertible. The CFC Index2 was applied to all patients. The
patients selected for this study are originally from Brazil




Genomic DNA was isolated from the patients’ peripheral-
blood leukocytes or from Epstein – Barr virus-transformed
lymphocytes using standard procedures.
Gene sequencing
The 15 exons of the PTPN11 gene, described at http://
genome.ucsc.edu//cgi-bin/hgTracks?position=NM 002834&
Submit=Submit and at http://www.ncbi.nlm.nih.gov/
entrez / viewer.fcgi?dispmax =1&showndispmax = 1&val = NT
009575.8&view=graph& from=758671& to=857626&
sfrom=0& strand=2, and their intron – exon boundaries
were sequenced bi-directionally (Table 1, Figure 2). These
Figure 1 Representation of the 12q24 chromosome region, microsatellite markers that span the Noonan syndrome critical region and
results of linkage studies in NS families. Microsatellite in bold corresponds to the PTPN11 localization.
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regions were amplified from genomic DNA using the
primers shown in Table 2, which were selected by the
Macintosh program Primer Express.
PRC reactions were carried out under standard condi-
tions, containing: 50 ng of genomic DNA, 1 mM of each
forward and reverse primers and 10 ml of Promega TAX
Master Mix, as follows: initial denaturation at 958C for
5 min, followed by 30 cycles of denaturation at 958C
(1 min), annealing at 53 – 608C (1 min) and extension at
728C (1 min), followed by final extension at 728C for
5 min, using the Gene Amp PCR System 9600 - Perkin
Elmer.
PRC products were purified with a PCR product pre-
sequencing kit, composed of exonuclease 1 and shrimp
alkaline phosphatase, by USB Corporation, according to
their instructions, and later using the Centri-Sep Spin
Columns by Applied Biosystems. Sequencing reactions were
carried out using the ABIPRISM dye terminator cycle
sequencing kit, and the products were analysed on an
ABIPRISM 310 Genetic Analyzer DNA sequencer. Sequences
were analysed manually.
Study of the cDNA
In order to detect the presence of deletions within the
coding region, which could be overlooked by analysing
the sequences, we constructed five pairs of primers to
amplify overlapping cDNA fragments of about 550 bp
(Table 3). These fragments were amplified by PCR, carried
out under standard conditions, containing: 50 ng of cDNA,
1 mM of each forward and reverse primers and 10 ml of
Figure 2 PTPN11 organization and SHP-2 structure.
P1 P2 P3
Figure 3 Three of the CFC patients studied. Patient 1, male, 28 years old; patient 2, male, 3 years old; patient 3, male, 8 years old.
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Promega TAX Master Mix, as follows: initial denaturation at
958C for 5 min, followed by 30 cycles of denaturation at
958C (1 min), annealing at 55 – 648C (1 min) and extension
at 728C (1.5 min), followed by extension period of 10 min,
using the Gene Amp PCR System 9600 - Perkin Elmer. Every
PCR reaction included 10 CFC patients and one control
subject. PCR products were electrophoresed on a 2% agar-
ose gel to verify the actual size of the fragments obtained
from each patient.
Results
The CFC Index of all ten patents included in this study
ranged from 71 SD to +1 SD. Three facial pictures are
shown in Figure 3.
Table 1 Intron – exon boundaries for the PTPN11 gene, exons length and their position in the mRNA (NM_002834). Intronic
sequences are represented in lower case, and exonic, in upper case
Exon PTPN11 Exon
Number intron/EXON. . . EXON/intron mRNA (bp) length (bp)
1 ggatcccccag/GCCTGGAGGG. . . CATCGCGGAG/gtgaggagcc 234-394 161
2 tctttttaag/ATGGTTTCAC. . . TTTCCGTTAG/gtaagttgga 397-517 123
3 actattttag/AAGAAATGGA. . . CCTCTGAAAG/gtcagtaaca 518-712 195
4 aaaactttag/GTGGTTTCAT. . . TCGCTGTCAG/caggtgagca 713-905 193
5 atcttgaaag/GAACTGAAAT. . . ACAACTCAAG/ctttctcctt 906-1022 117
6 actcgatcag/CCCCTTAACA. . . AGAATTTGAG/gtaagttatt 1023-1136 114
7 ttctttccag/ACACTACAAC. . . ATCCTGCCCT/gtaagtatca 1137-1233 97
8 tttcttctag/TTGATCATAC. . . TATCATCATG/gtaagctttg 1234-1313 80
9 aaatttctag/CCTGAATTTG. . . GAGAGGAAAG/gtaaatcaca 1314-1472 159
10 tctcttccag/AGTAAATGTG. . . GGTTGGACAA/gtaagtatat 1473-1604 132
11 tctactccag/GGGAATACGG . . . TGCACTGCAG/gtgacagctc 1605-1759 155
12 ctgcccgcag/TGCTGGAATT. . . AGAGAGAAAG/gtgggtcatc 1760-1827 68
13 tccttcgtag/GTGTTGACTG. . . AGAAGAGCAG/gtaccagcct 1828-1979 152
14 caaatttcag/AAAAGCAAGA. . . CCTGTGCAGA/gtaagtagtg 1980-2092 113
15 ttctctccag/AATGAGAGAA. . . ACAGAAATAG/gtatttaaat 2093-2194 102
Table 2 Primers and PCR conditions used to amplify the coding region of the PTPN11 gene
Primer forward Primer reverse Exon T annealing Size of the
Exon (5’?3’) (5’?3’) length (bp) (8C) PCR product
1 GCTGACGGGAAGCAGGAAGTGG CTGGCACCCGTGGTTCCCTC 161 60 589
2 ACTGAATCCCAGGTCTCTACCAAG CAGCAAGCTATCCAAGCATGGT 123 60 405
3 TTA GAA GAA ATG GAG CTG TCA GAG ACT CAG GGC ACA AGG 195 55 254
4 AAC AAC ATG AAC CCA TAG TAG AGC CCA TTT TTC AAC TGG AGA TTT AC 193 57 271
5 ATG TGT TTA TCT TGA AAG GAA CT AAA ATT CTC TAT TAG GAT TTG TTT T 117 53 201
6 GCA TTA ACA CCG TTT TCT GTA AT GCA ACT TCT CCT CCA CTA AAA AT 114 58 241
7 ATG CTG ATC CAG GCT TTT TT GAG TGA CTA TTA CTG AGC GGA A 97 55 205
8/9 GCA GTC CAG GAC TTA TGT GA AAA CAT GGC CAA TCT GAC A 80/159 55 477
10 TTT CAG AGT TCA CAG AAT TAA CTT T ATT CCT ACA CAC CAT CAA CAG T 132 58 235
11 CGG GTG ATT CCT CAA CCT CTT G GCG CTA GGA GAC AGG GAC AGG 155 60 272
12 TTG AGT CTG AAA CCC CCA TG TGT TTT CGT GAG CAC TTT CC 68 55 201
13 TCT TCA TGA TGT TTC CTT CGT A GCC TAG CAA GAG AAT GAG AAT C 152 60 222
14 ATC CCC TTA AAA TAA CCA TTG T GAC CAG GTA AAA AGA ATT TCC T 113 55 201
15 TTT TGT AAA TGT CTT TCT TTT TCT T AAT TAT GGT ACA CTT TGC TAA AAC A 102 55 240
Table 3 Primes and PCR conditions to amplify overlapping fragments of PTPN11 cDNA
cDNA T Size of
position from Primer forward Primer reverse annealing PCR
the ATG (5’?3’) (5’?3’) (8C) product
769 to 544 gatgtgaccgagcccagg caacgtcgtatttcagttcctgac 64 613
246 to 811 ggaacatcacgggcaattaaa gcctttgaccctcttttcgg 58 566
696 to 1269 actaagcaaattagctgagaccacaga ccaggtccgaaagtggtattg 64 574
1135 to 1696 gaatatggcgtcatgcgtgt ttggagtacaaggcgggaga 55 562
1484 to 1874 agatggtgcggtctcagagg tcacataaactttcttgcgtctgtt 55 391
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The coding-region of PTPN11 and its intron – exon
boundary regions were sequenced in 10 CFC patients and
no base changes were identified.
The sizes of the amplified cDNA fragments were as
expected and single bands were detected from all patients
in all five fragments.
Discussion
The actual relationship between CFC and Noonan
syndromes has been the object of a heated controversy,
and many opinions have been expressed as to whether they
are different genetic entities, allelic conditions, a contigu-
ous gene syndrome, or even different phenotypes of the
same condition.2 – 5,13 – 15 The finding of one of the causes
of Noonan syndrome is a very important step towards the
clarification of this matter.
The protein encoded by PTPN11 is a member of the
protein tyrosine phosphatase (PTP) family. PTPs regulate a
variety of cellular processes, including cell growth, differen-
tiation, mitotic cycle and oncogenic transformation and, in
mouse, is involved in cardiac semilunar valvogenesis.16 The
finding of 45 – 50% PTPN11 mutation prevalence in a
sample of Noonan syndrome patients with almost 100%
penetrance9,11 demonstrates that it is one of the genes caus-
ing Noonan syndrome. Mutations found in NS patients
were all missense changes affecting amino acid residues
that are conserved among the vertebrate SHP-2 orthologs.
PTPN11 mutations have also been found in conditions
such as the Multiple-Lentigines/LEOPARD syndrome12 and
Noonan-like/multiple giant-cell lesion syndrome.11 These
data are of great importance in extending the phenotype
of Noonan syndrome. It is also important to better classify
some patients whose diagnosis is controversial. The finding
of the same PTPN11 mutation in the two patients from a
large family with NS who were previously diagnosed as
having CFC syndrome17,18 demonstrates that those patients
also have Noonan syndrome as already evident by their
published phenotype. Therefore, to date, there are no famil-
ial cases of CFC syndrome. We have demonstrated that CFC
syndrome patients do not have missense changes on the
coding region of the PTPN11, nor small or large intragenic
deletions, which we regard as molecular evidence that CFC
and Noonan syndromes are distinct genetic entities.
We encourage PTPN11 mutation screening in other CFC
patients to confirm our results.
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